3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
17
Cisplatin
11
Carboplatin
9
Cyclophosphamide
8
fludarabine
6
Paclitaxel
6
Nivolumab
6
Bevacizumab
6
aldesleukin
5
Radiotherapy
5
toripalimab
4
tisotumab vedotin
4
fludarabine phosphate
4
Topotecan
4
Interleukin-2
4
Docetaxel
4
Brachytherapy
4
spartalizumab
3
Ipilimumab
3
Fulvestrant
3
ferumoxtran-10
2
enzalutamide
2
durvalumab
2
cemiplimab
2
bemarituzumab
2
balstilimab
2
Trastuzumab
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Uterine Cervical Neoplasms
×
STX-478
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled